Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.52 USD
Change Today -0.09 / -2.49%
Volume 29.9K
VCEL On Other Exchanges
As of 8:10 PM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

vericel corp (VCEL) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/15 - $4.35
52 Week Low
09/23/14 - $2.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VERICEL CORP (VCEL)

Related News

No related news articles were found.

vericel corp (VCEL) Related Businessweek News

No Related Businessweek News Found

vericel corp (VCEL) Details

Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.

190 Employees
Last Reported Date: 03/25/15
Founded in 1989

vericel corp (VCEL) Top Compensated Officers

Chief Executive Officer, President, Treasurer...
Total Annual Compensation: $519.6K
Chief Financial Officer, Vice President of Co...
Total Annual Compensation: $204.2K
Chief Operating Officer
Total Annual Compensation: $337.7K
Compensation as of Fiscal Year 2014.

vericel corp (VCEL) Key Developments

Vericel to Submit MACI Biologics License Application to U.S. Food and Drug Administration by Year-End of 2015

Vericel announced that following discussions with the U.S. Food and Drug Administration it plans to submit a Biologics License Application (BLA) by the end of 2015 for MACI for the treatment of focal chondral cartilage defects in the knee. MACI (matrix-applied characterized autologous cultured chondrocytes) is a third-generation autologous chondrocyte implantation (ACI) product for the treatment of cartilage defects in the knee.

Vericel Corporation Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Vericel Corporation announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $10,849,000. Loss from operations was $4,572,000 against $4,645,000 a year ago. Net loss was $4,862,000 against $5,995,000 a year ago. Basic and diluted net loss per share attributable to common shareholders was $0.27 against $1.26 a year ago.

Vericel Corporation - Shareholder/Analyst Call

Annual Meeting of Shareholders


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCEL:US $3.52 USD -0.09

VCEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.19 USD -0.03
Caladrius Biosciences Inc $1.91 USD +0.06
Cesca Therapeutics Inc $0.78 USD -0.042
Cytori Therapeutics Inc $0.53 USD -0.0178
TiGenix NV €0.70 EUR -0.006
View Industry Companies

Industry Analysis


Industry Average

Valuation VCEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERICEL CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at